GI Stool Testing Market - By Product Type, By Test Type, By Application, By Distribution Channel, By End-use, & Forecast, 2023

Description

List of Tables

Global GI Stool Testing Market will witness significant growth between 2023 and 2032. The escalating prevalence of gastrointestinal disorders has heightened the demand for non-invasive diagnostic tools, fuelling market growth. According to the CDC, approximately 1 in 6 Americans (or 48 million people) get sick each year, 128,000 are admitted to hospitals, and 3,000 individuals die of foodborne illnesses.

The shift towards personalized medicine drives the adoption of targeted therapies, necessitating accurate diagnostic insights provided by stool testing. Additionally, technological upgrades enable more sensitive and specific tests, enhancing their clinical utility. The growing awareness of early disease den and preventive healthcare further amplifies market expansion. Moreover, the convenience and cost-effectiveness of stool tests compared to invasive procedures solidify their position in the diagnostics landscape, driving the GI stool testing industry forward.

The overall GI Stool Testing Market is classified based on product type, test type, application, and region.

Based on product type, the analyzers segment will demonstrate noticeable expansion during 2023-2032. These sophisticated devices offer rapid and accurate analysis of stool samples, aiding in the diagnosis of various gastrointestinal disorders. With an increasing emphasis on early detection and personalized treatment, healthcare professionals rely on these analyzers to provide precise insights for informed decision-making. Their efficiency, automation, and ability to handle a high volume of samples make them essential tools in modern diagnostics, driving their demand in the GI stool testing market.

By test type, the ova and parasites test segment will strengthen the GI stool testing market outlook through 2032. This test type helps identify microscopic parasites and their eggs, shedding light on infections that might otherwise go undetected. As global travel and food consumption rise, so does the risk of parasitic infections. Thus, the accuracy and early detection capabilities of ova and parasite testing contribute significantly to its demand, addressing a crucial aspect of gastrointestinal health.

Regarding the application, the gastroesophageal reflux disease segment could dominate the GI stool testing market share by 2032. GERD, a common digestive disorder, requires accurate assessment to guide treatment decisions. Stool testing offers a non-invasive method to analyze biomarkers related to inflammation, digestion, and gut health, aiding in GERD diagnosis and management. This demand stems from the pursuit of effective, patient-centric solutions for a prevalent condition that impacts millions worldwide. Therefore, the rising need for GERD diagnostics supports the GI stool testing market.

Regionally, the European GI stool testing industry will gain traction during the forecast period due to the region's aging population and increasing prevalence of gastrointestinal disorders. Additionally, rising awareness about preventive healthcare fuels the adoption of stool testing for early disease detection. European healthcare systems' emphasis on cost-effective solutions further boosts the market, with advancements in technology and diagnostic accuracy solidifying stool testing's role in

maintaining gastrointestinal wellness across the continent.

Product Code: 5719

Chapter 1 Methodology & Scope

1.1 Industry coverage
1.2 Market scope & definition
1.3 Base estimates & calculations
- 1.3.1 Data collection
1.4 Forecast parameters
1.5 COVID-19 impact analysis at global level
1.6 Data validation
1.7 Data Sources
- 1.7.1 Primary
- 1.7.2 Secondary
  - 1.7.2.1 Paid sources
  - 1.7.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 GI stool testing industry 360 degree synopsis, 2018 - 2032
2.2 Business trends
2.3 Regional trends
2.4 Product type trends
2.5 Test type trends
2.6 Application trends
2.7 Distribution channel trends
2.8 End-use trends

Chapter 3 GI Stool Testing Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increase in prevalence of Gastrointestinal disorders
  - 3.2.1.2 Technological advancements
  - 3.2.1.3 Rising demand for point-of-care (POC) testing
  - 3.2.1.4 Growing demand for early diagnosis and prevention of GI diseases
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Lack of skilled professionals
  - 3.2.2.2 Stringent regulatory policies
3.3 Growth potential analysis
- 3.3.1 By product type
- 3.3.2 By test type
- 3.3.3 By application
- 3.3.4 By distribution channel
- 3.3.5 By end use
3.4 COVID- 19 impact analysis
3.5 Pricing analysis, 2022
3.6 Regulatory landscape
- 3.6.1 U.S.
- 3.6.2 Europe
3.7 Technology landscape
3.8 Reimbursement scenario
3.9 Future market trends
3.10 Gap analysis
3.11 Porter's analysis
3.12 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Company market share analysis, 2022
4.4 Competitive positioning matrix
4.5 Vendor matrix analysis
4.6 Strategy dashboard

Chapter 5 GI Stool Testing Market Size and Forecast, By Product Type (USD Million & Units)

5.1 Key trends, by product type
5.2 Consumables
5.3 Analyzers

Chapter 6 GI Stool Testing Market Size and Forecast, By Test Type (USD Million)

6.1 Key trends, by test type
6.2 Occult blood test
- 6.2.1 Guaiac FOB stool test
- 6.2.2 Immuno FOB agglutination test
- 6.2.3 Lateral flow immuno FOB test
- 6.2.4 Immuno FOB ELISA test
6.3 Ova and parasites test
6.4 Bacteria test
6.5 Fecal biomarkers test
- 6.5.1 Tumor M2-PK stool test
- 6.5.2 Transferrin assays
- 6.5.3 Others
6.6 Others

Chapter 7 GI Stool Testing Market Size and Forecast, By Application (USD Million)

7.1 Key trends, by application
7.2 Infection
7.3 Inflammatory bowel disease
7.4 Gastroesophageal reflux disease (GERD)
7.5 Cancer
7.6 Others

Chapter 8 GI Stool Testing Market Size and Forecast, By Distribution Channel (USD Million)

8.1 Key trends, by distribution channel
8.2 Hospital & clinics pharmacies
8.3 Brick & Mortar
8.4 E-commerce

Chapter 9 GI Stool Testing Market Size and Forecast, By End-use (USD Million)

9.1 Key trends, by end-use
9.2 Hospitals & clinics
9.3 Diagnostic centers
9.4 Homecare settings
9.5 Others

Chapter 10 GI Stool Testing Market Size and Forecast, By Region (USD Million & Units)

10.1 Key trends, by region
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Poland
- 10.3.7 Sweden
- 10.3.8 The Netherlands
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Thailand
- 10.4.7 Indonesia
- 10.4.8 Philippines
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
- 10.5.4 Columbia
- 10.5.5 Chile
- 10.5.6 Peru
10.6 MEA
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
- 10.6.4 Israel
- 10.6.5 Turkey
- 10.6.6 Iran

Chapter 11 Company Profiles

11.1 Abbott Laboratories
11.2 Alere Inc.
11.3 Beckman Coulter Inc.
11.4 Bio Rad Laboratories
11.5 BioMrieux Inc
11.6 Cardinal Health
11.7 Cenogenics Corporation
11.8 CTK Biotech Inc.
11.9 Danaher Corporation (Beckman Coulter, Inc.)
11.10 DiaSorin S.p.A.
11.11 Epitope Diagnostics Inc.
11.12 Genova Diagnostics
11.13 Meridian Bioscience Inc
11.14 Quest Diagnostics Incorporated
11.15 ScheBo Biotech AG
11.16 Siemens Healthcare